NeuroFrontiers
Clinical research and advancements furthering clinicians’ ability to diagnose and treat neurological disorders never stop. And neither does NeuroFrontiers, a series dedicated to covering them all. Here neurology specialists will find essential updates on conditions affecting the nervous system, spinal cord, and overall brain health.
So if you want to stay up to date on the latest clinical research and news on neurological disorders, then look no further. Because NeuroFrontiers is where neurology specialists and great minds explore the mind itself.
91-105 of 388
Genetic Pathways in MS: The Clinical Impact of a Chromosome 2 Variant
NeuroFrontiersGenetic Pathways in MS: The Clinical Impact of a Chromosome 2 Variant
Sergio Baranzini, PhD
Understanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS
NeuroFrontiersUnderstanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS
Michael Levy, MD, PhD
Navigating MS Diagnosis in Older Adults: Distinguishing Comorbidities and Mimics
NeuroFrontiersNavigating MS Diagnosis in Older Adults: Distinguishing Comorbidities and Mimics
Le Hua, MD
Decoding Disability Worsening in MS: The Case for Combining CSF and Serum Biomarkers
NeuroFrontiersDecoding Disability Worsening in MS: The Case for Combining CSF and Serum Biomarkers
Ryan Quigley
Timing Matters: Influenza Vaccination Response in MS Patients on Ofatumumab
NeuroFrontiersTiming Matters: Influenza Vaccination Response in MS Patients on Ofatumumab
Clemastine Fumarate and Progressive MS: A Closer Look at Unexpected Risks and Mechanisms
NeuroFrontiersClemastine Fumarate and Progressive MS: A Closer Look at Unexpected Risks and Mechanisms
- advertisement
Transforming Alzheimer’s Care: Anti-Amyloid Therapies and Emerging Genetic Approaches
NeuroFrontiersTransforming Alzheimer’s Care: Anti-Amyloid Therapies and Emerging Genetic Approaches
Marc Haut, PhD
Advances in Alzheimer’s Diagnosis: From Imaging to Artificial Intelligence
NeuroFrontiersAdvances in Alzheimer’s Diagnosis: From Imaging to Artificial Intelligence
Marc Haut, PhD
The Future of MS Management: Novel Agents and Clinical Approaches
NeuroFrontiersThe Future of MS Management: Novel Agents and Clinical Approaches
Marisa McGinley, DO
Reevaluating Natalizumab Dosing in RRMS: Insights from the NOVA Trial
NeuroFrontiersReevaluating Natalizumab Dosing in RRMS: Insights from the NOVA Trial
Modern MS Care: Navigating Treatment Options for Better Patient Outcomes
NeuroFrontiersModern MS Care: Navigating Treatment Options for Better Patient Outcomes
Pregnancy and Infant Outcomes in Multiple Sclerosis: Findings from the MAPLE-MS Pharmacovigilance Program
NeuroFrontiersPregnancy and Infant Outcomes in Multiple Sclerosis: Findings from the MAPLE-MS Pharmacovigilance Program
- advertisement
Recognizing MS: Understanding Symptoms and Avoiding Misdiagnosis
NeuroFrontiersRecognizing MS: Understanding Symptoms and Avoiding Misdiagnosis
MS Relapse vs Pseudo-Relapse After Infection: COVID-19 Shows Divergent Risk Pattern
NeuroFrontiersMS Relapse vs Pseudo-Relapse After Infection: COVID-19 Shows Divergent Risk Pattern
Epigenetic Immune Signatures in Alzheimer’s: Implications for Diagnosis and Therapy
NeuroFrontiersEpigenetic Immune Signatures in Alzheimer’s: Implications for Diagnosis and Therapy
David Gate, PhD
